Table of Contents

company-logo

OSE Immunotherapeutics SA focuses on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. Its products include Tedopi that is in Phase III clinical stage for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; CoVepiT, a prophylactic vaccine against the SARS-CoV-2 virus; BI 765063, which is in Phase I clinical trial to treat solid tumors; and BiCKI, a novel bispecific checkpoint inhibitor platform, targeting PD-1 and innovative targets to fight primary and secondary resistance mechanisms developed by cancers. The company's products also comprise OSE-127, a humanized monoclonal antibody that is in Phase II clinical trial for the treatment of ulcerative colitis, as well as Sjögren's Syndrome; FR104, which is in Phase I clinical trial for the treatment of rheumatoid arthritis; and OSE-230, an agonist antibody against ChemR23 to resolve chronic inflammation. OSE Immunotherapeutics SA has collaborations and partnerships with GERCOR, Boehringer Ingelheim, Servier, and Chong Kun Dang Pharmaceutical Corporation. The company was formerly known as OSE Pharma SA and changed its name to OSE Immunotherapeutics SA in May 2016. OSE Immunotherapeutics SA is headquartered in Nantes, France.

OSE Immunotherapeutics Dividend Announcement

• OSE Immunotherapeutics does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on OSE Immunotherapeutics dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

OSE Immunotherapeutics Dividend History

OSE Immunotherapeutics Dividend Yield

OSE Immunotherapeutics current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing OSE Immunotherapeutics stock? Use our calculator to estimate your expected dividend yield:

OSE Immunotherapeutics Financial Ratios

P/E ratio4.59
PEG ratio0.05
P/B ratio2.59
ROE88.29%
Payout ratio0.00%
Current ratio4.93
Quick ratio4.79
Cash Ratio4.36

OSE Immunotherapeutics Dividend FAQ

Does OSE Immunotherapeutics stock pay dividends?
OSE Immunotherapeutics does not currently pay dividends to its shareholders.
Has OSE Immunotherapeutics ever paid a dividend?
No, OSE Immunotherapeutics has no a history of paying dividends to its shareholders. OSE Immunotherapeutics is not known for its dividend payments.
Why doesn't OSE Immunotherapeutics pay dividends?
There are several potential reasons why OSE Immunotherapeutics would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will OSE Immunotherapeutics ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While OSE Immunotherapeutics has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is OSE Immunotherapeutics a dividend aristocrat?
OSE Immunotherapeutics is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is OSE Immunotherapeutics a dividend king?
OSE Immunotherapeutics is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is OSE Immunotherapeutics a dividend stock?
No, OSE Immunotherapeutics is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy OSE Immunotherapeutics stocks?
To buy OSE Immunotherapeutics you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy OSE Immunotherapeutics stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.